or Try an Advanced Search...

    Technical Analysis for SPRB - Spruce Biosciences, Inc.

    Grade Last Price % Change Price Change
    D 0.55 3.20% 0.02
    SPRB closed up 3.2 percent on Friday, November 1, 2024, on 77 percent of normal volume.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical SPRB trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Support Bullish 3.20%
    1,2,3 Pullback Bullish Bullish Swing Setup 3.20%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.20%
    Wide Bands Range Expansion 3.20%
    Overbought Stochastic Strength 3.20%
    Gapped Down Weakness 3.20%
    Calm After Storm Range Contraction -2.90%
    Wide Bands Range Expansion -2.90%
    Older End-of-Day Signals for SPRB ...

       Recent Intraday Alerts

    Alert Time
    Non-ADX 1,2,3,4 Pullback Entry about 22 hours ago
    1,2,3, Pullback Entry about 22 hours ago
    Rose Above Previous Day's High about 22 hours ago
    60 Minute Opening Range Breakout 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    SPRB Chart by TradingView
    Basic chart:

    Profile

    Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Hyperplasia Endocrine Disorders Congenital Adrenal Hyperplasia Neurocrine Biosciences

    Is SPRB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 28 Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
    Sep 3 Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 13 Spruce Biosciences GAAP EPS of -$0.22 beats by $0.01, revenue of $1.61M beats by $0.69M
    Aug 12 Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
    Aug 12 Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
    Jun 24 Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
    Jun 6 Spruce Biosciences Recognized as a Bay Area Best Place to Work
    Jun 4 Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
    Jun 4 Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
    Jun 3 Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
    See more SPRB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.95
    52 Week Low 0.4112
    Average Volume 420,359
    200-Day Moving Average 1.31
    50-Day Moving Average 0.48
    20-Day Moving Average 0.52
    10-Day Moving Average 0.56
    Average True Range 0.04
    RSI (14) 56.90
    ADX 34.92
    +DI 22.93
    -DI 21.21
    Chandelier Exit (Long, 3 ATRs) 0.50
    Chandelier Exit (Short, 3 ATRs) 0.53
    Upper Bollinger Bands 0.62
    Lower Bollinger Band 0.41
    Percent B (%b) 0.65
    BandWidth 42.02
    MACD Line 0.03
    MACD Signal Line 0.03
    MACD Histogram 0.0016
    Fundamentals Value
    Market Cap 22.32 Million
    Num Shares 40.7 Million
    EPS -1.48
    Price-to-Earnings (P/E) Ratio -0.37
    Price-to-Sales 24.67
    Price-to-Book 1.90
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.59
    Resistance 3 (R3) 0.59 0.57 0.58
    Resistance 2 (R2) 0.57 0.56 0.57 0.58
    Resistance 1 (R1) 0.56 0.55 0.57 0.56 0.58
    Pivot Point 0.54 0.54 0.55 0.55 0.54
    Support 1 (S1) 0.53 0.53 0.54 0.53 0.52
    Support 2 (S2) 0.52 0.53 0.52 0.52
    Support 3 (S3) 0.51 0.52 0.51
    Support 4 (S4) 0.51